• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Neurological manifestations of autosomal dominant familial Alzheimer ’s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)
Publication date: December 2016 Source:The Lancet Neurology, Volume 15, Issue 13 Author(s): Mengxuan Tang, Davis C Ryman, Eric McDade, Mateusz S Jasielec, Virginia D Buckles, Nigel J Cairns, Anne M Fagan, Alison Goate, Daniel S Marcus, Chengjie Xiong, Ricardo F Allegri, Jasmeer P Chhatwal, Adrian Danek, Martin R Farlow, Nick C Fox, Bernardino Ghetti, Neill R Graff-Radford, Christopher Laske, Ralph N Martins, Colin L Masters, Richard P Mayeux, John M Ringman, Martin N Rossor, Stephen P Salloway, Peter R Schofield, John C Morris, Randall J Bateman Background Autosomal dominant familial Alzheimer’s disease (ADAD) is a rare...
Source: The Lancet Neurology - November 7, 2016 Category: Neurology Source Type: research

Impaired consciousness in patients with absence seizures investigated by functional MRI, EEG, and behavioural measures: a cross-sectional study
Publication date: December 2016 Source:The Lancet Neurology, Volume 15, Issue 13 Author(s): Jennifer N Guo, Robert Kim, Yu Chen, Michiro Negishi, Stephen Jhun, Sarah Weiss, Jun Hwan Ryu, Xiaoxiao Bai, Wendy Xiao, Erin Feeney, Jorge Rodriguez-Fernandez, Hetal Mistry, Vincenzo Crunelli, Michael J Crowley, Linda C Mayes, R Todd Constable, Hal Blumenfeld Background The neural underpinnings of impaired consciousness and of the variable severity of behavioural deficits from one absence seizure to the next are not well understood. We aimed to measure functional MRI (fMRI) and electroencephalography (EEG) changes in absence seizu...
Source: The Lancet Neurology - November 7, 2016 Category: Neurology Source Type: research

DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study
Publication date: Available online 28 September 2016 Source:The Lancet Neurology Author(s): Joanne Trinh, Emil K Gustavsson, Carles Vilariño-Güell, Stephanie Bortnick, Jeanne Latourelle, Marna B McKenzie, Chelsea Szu Tu, Ekaterina Nosova, Jaskaran Khinda, Austen Milnerwood, Suzanne Lesage, Alexis Brice, Meriem Tazir, Jan O Aasly, Laura Parkkinen, Hazal Haytural, Tatiana Foroud, Richard H Myers, Samia Ben Sassi, Emna Hentati, Fatma Nabli, Emna Farhat, Rim Amouri, Fayçal Hentati, Matthew J Farrer Background Leucine-rich repeat kinase 2 (LRRK2) mutation 6055G→A (Gly2019Ser) accounts for roughly 1% of patients with Parki...
Source: The Lancet Neurology - September 28, 2016 Category: Neurology Source Type: research

Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial
Publication date: Available online 23 August 2016 Source:The Lancet Neurology Author(s): Kevin N Sheth, Jordan J Elm, Bradley J Molyneaux, Holly Hinson, Lauren A Beslow, Gordon K Sze, Ann-Christin Ostwaldt, Gregory J del Zoppo, J Marc Simard, Sven Jacobson, W Taylor Kimberly Background Preclinical models of stroke have shown that intravenous glyburide reduces brain swelling and improves survival. We assessed whether intravenous glyburide (RP-1127; glibenclamide) would safely reduce brain swelling, decrease the need for decompressive craniectomy, and improve clinical outcomes in patients presenting with a large hemispheric...
Source: The Lancet Neurology - August 23, 2016 Category: Neurology Source Type: research

Efficacy and safety of non-immersive virtual reality exercising in stroke rehabilitation (EVREST): a randomised, multicentre, single-blind, controlled trial
Publication date: September 2016 Source:The Lancet Neurology, Volume 15, Issue 10 Author(s): Gustavo Saposnik, Leonardo G Cohen, Muhammad Mamdani, Sepideth Pooyania, Michelle Ploughman, Donna Cheung, Jennifer Shaw, Judith Hall, Peter Nord, Sean Dukelow, Yongchai Nilanont, Felipe De los Rios, Lisandro Olmos, Mindy Levin, Robert Teasell, Ashley Cohen, Kevin Thorpe, Andreas Laupacis, Mark Bayley Background Non-immersive virtual reality is an emerging strategy to enhance motor performance for stroke rehabilitation. There has been rapid adoption of non-immersive virtual reality as a rehabilitation strategy despite the limited ...
Source: The Lancet Neurology - August 8, 2016 Category: Neurology Source Type: research

Global burden of stroke and risk factors in 188 countries, during 1990 –2013: a systematic analysis for the Global Burden of Disease Study 2013
Publication date: August 2016 Source:The Lancet Neurology, Volume 15, Issue 9 Author(s): Valery L Feigin, Gregory A Roth, Mohsen Naghavi, Priya Parmar, Rita Krishnamurthi, Sumeet Chugh, George A Mensah, Bo Norrving, Ivy Shiue, Marie Ng, Kara Estep, Kelly Cercy, Christopher J L Murray, Mohammad H Forouzanfar Background The contribution of modifiable risk factors to the increasing global and regional burden of stroke is unclear, but knowledge about this contribution is crucial for informing stroke prevention strategies. We used data from the Global Burden of Disease Study 2013 (GBD 2013) to estimate the popul...
Source: The Lancet Neurology - July 20, 2016 Category: Neurology Source Type: research

Functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care: an observational registry study
This study is registered with ClinicalTrials.gov, number NCT02358772. Findings Between Feb 5, 2011, and March 5, 2015, 427 patients were treated within the STEMO vehicle and their data were entered into a pre-hospital registry. 505 patients received conventional care and their data were entered into an in-hospital thrombolysis registry. Of these, 305 patients in the STEMO group and 353 in the conventional care group met inclusion criteria and were included in the analysis. 161 (53%) patients in the STEMO group versus 166 (47%) in the conventional care group had an mRS score of 1 or lower (p=0·14). Compared with conventio...
Source: The Lancet Neurology - July 15, 2016 Category: Neurology Source Type: research

Editorial The shared burden of stroke and dementia
The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has enabled researchers to understand the epidemiology of global health in a systematic way that has not been possible before. Collaborators of the GBD, with funding from the Bill & Melinda Gates Foundation, collate global epidemiological data to generate estimates of mortality and morbidity, which are presented by age, sex, region, and economic status. The most recent overall GBD update, published in The Lancet, provided estimates of the years lived with disability for many neurological diseases, but did not assess the contribution of associated risk fa...
Source: Lancet Neurology - July 12, 2016 Category: Neurology Authors: The Lancet Neurology Tags: Editorial Source Type: research

Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
Publication date: Available online 9 June 2016 Source:The Lancet Neurology Author(s): Valery L Feigin, Gregory A Roth, Mohsen Naghavi, Priya Parmar, Rita Krishnamurthi, Sumeet Chugh, George A Mensah, Bo Norrving, Ivy Shiue, Marie Ng, Kara Estep, Kelly Cercy, Christopher J L Murray, Mohammad H Forouzanfar Background The contribution of modifiable risk factors to the increasing global and regional burden of stroke is unclear, but knowledge about this contribution is crucial for informing stroke prevention strategies. We used data from the Global Burden of Disease Study 2013 (GBD 2013) to estimate the populati...
Source: The Lancet Neurology - June 9, 2016 Category: Neurology Source Type: research

Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis
Publication date: Available online 8 June 2016 Source:The Lancet Neurology Author(s): William N Whiteley, Jonathan Emberson, Kennedy R Lees, Lisa Blackwell, Gregory Albers, Erich Bluhmki, Thomas Brott, Geoff Cohen, Stephen Davis, Geoffrey Donnan, James Grotta, George Howard, Markku Kaste, Masatoshi Koga, Rüdiger von Kummer, Maarten G Lansberg, Richard I Lindley, Patrick Lyden, Jean Marc Olivot, Mark Parsons, Danilo Toni, Kazunori Toyoda, Nils Wahlgren, Joanna Wardlaw, Gregory J del Zoppo, Peter Sandercock, Werner Hacke, Colin Baigent Background Randomised trials have shown that alteplase impr...
Source: The Lancet Neurology - June 8, 2016 Category: Neurology Source Type: research

Dementia risk after spontaneous intracerebral haemorrhage: a prospective cohort study
Publication date: July 2016 Source:The Lancet Neurology, Volume 15, Issue 8 Author(s): Solène Moulin, Julien Labreuche, Stéphanie Bombois, Costanza Rossi, Gregoire Boulouis, Hilde Hénon, Alain Duhamel, Didier Leys, Charlotte Cordonnier Background Dementia occurs in at least 10% of patients within 1 year after stroke. However, the risk of dementia after spontaneous intracerebral haemorrhage that accounts for about 15% of all strokes has not been investigated in prospective studies. We aimed to determine the incidence of dementia and risk factors after an intracerebral haemorrhage. Methods We did a prospective...
Source: The Lancet Neurology - June 6, 2016 Category: Neurology Source Type: research

Effect of baseline Alberta Stroke Program Early CT Score on safety and efficacy of intra-arterial treatment: a subgroup analysis of a randomised phase 3 trial (MR CLEAN)
We examined the effect of the baseline Alberta Stroke Program Early CT Score (ASPECTS) on the safety and efficacy of intra-arterial treatment in a subgroup analysis of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN). Methods MR CLEAN was a randomised, controlled, open-label, phase 3 trial of intra-arterial treatment in patients (aged ≥18 years from the Netherlands) with proximal arterial occlusion of the anterior circulation, given intra-arterial treatment within 6 h of stroke onset. The primary outcome was 90 day modified Rankin Scale (mRS) sco...
Source: The Lancet Neurology - May 11, 2016 Category: Neurology Source Type: research

Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial
Publication date: May 2016 Source:The Lancet Neurology, Volume 15, Issue 6 Author(s): Thorsten Steiner, Sven Poli, Martin Griebe, Johannes Hüsing, Jacek Hajda, Anja Freiberger, Martin Bendszus, Julian Bösel, Hanne Christensen, Christian Dohmen, Michael Hennerici, Jennifer Kollmer, Henning Stetefeld, Katja E Wartenberg, Christian Weimar, Werner Hacke, Roland Veltkamp Background Haematoma expansion is a major cause of mortality in intracranial haemorrhage related to vitamin K antagonists (VKA-ICH). Normalisation of the international normalised ratio (INR) is recommended, but optimum haemostatic managemen...
Source: The Lancet Neurology - April 19, 2016 Category: Neurology Source Type: research

Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies
Publication date: Available online 7 April 2016 Source:The Lancet Neurology Author(s): Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) ConsortiumStroke Genetics Network (SiGN)International Stroke Genetics Consortium (ISGC) Background Genetic determinants of stroke, the leading neurological cause of death and disability, are poorly understood and have seldom been explored in the general population. Our aim was to identify additional loci for stroke by doing a meta-analysis of genome-wide association studies. Methods For the discovery sample, we did a genome-wide analys...
Source: The Lancet Neurology - April 7, 2016 Category: Neurology Source Type: research

Translational Hurdles in Stroke Recovery Studies
Abstract Emerging understanding of brain plasticity has opened new avenues for the treatment of stroke. The promising preclinical evidence with neuroprotective drugs has not been confirmed in clinical trials, thus nowadays, researchers, pharmaceutical companies, and funding bodies hesitate to initiate these expensive trials with restorative therapies. Since many of the previous failures can be traced to low study quality, a number of guidelines such as STAIR and STEPS were introduced to rectify these shortcomings. However, these guidelines stem from the study design for neuroprotective drugs and one may question w...
Source: Translational Stroke Research - March 22, 2016 Category: Neurology Source Type: research

Pages: 1  2  3  4  5